Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

This study tests an oncolytic virus therapy called RP2 (a specially engineered herpes virus that attacks tumour cells) combined with second-line cancer treatments in two groups: people with liver cancer (HCC) that progressed after immunotherapy, and people with advanced bile duct/gallbladder cancer (BTC) who are currently on standard first-line treatment. RP2 is injected directly into tumours to trigger an immune response against the cancer. **You may be eligible if...** - You are 18 or older - (For liver cancer): You have advanced liver cancer that progressed while on a first-line immunotherapy-containing regimen - (For bile duct/gallbladder cancer): You have advanced disease currently on first-line chemotherapy plus immunotherapy for at least 12 weeks - You have at least one tumour that can be directly injected - Your liver function, blood counts, and organ function meet minimum thresholds - You are in good overall health (ECOG 0 or 1) **You may NOT be eligible if...** - You have active herpes infections, or a history of serious herpes complications - You have untreated variceal bleeding or liver disease that is too advanced (Child-Pugh B or C) - You have HIV, active tuberculosis, or serious uncontrolled infection - You have had a prior oncolytic virus therapy - You are pregnant or breastfeeding - You have a serious autoimmune disease requiring systemic treatment - You have had a recent heart attack or severe heart failure Talk to your doctor to see if this trial is right for you.